BACVAX Trademark

Trademark Overview

On Wednesday, March 10, 2021, a trademark application was filed for BACVAX with the United States Patent and Trademark Office. The USPTO has given the BACVAX trademark a serial number of 90571039. The federal status of this trademark filing is REGISTERED as of Tuesday, April 1, 2025. This trademark is owned by BacVax, Inc.. The BACVAX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Vaccine research and development
bacvax

General Information

Serial Number90571039
Word MarkBACVAX
Filing DateWednesday, March 10, 2021
Status700 - REGISTERED
Status DateTuesday, April 1, 2025
Registration Number7746844
Registration DateTuesday, April 1, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 9, 2021

Trademark Statements

Goods and ServicesVaccine research and development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 10, 2021
Primary Code042
First Use Anywhere DateMonday, June 10, 2024
First Use In Commerce DateMonday, June 10, 2024

Trademark Owner History

Party NameBacVax, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressPhoenix, AZ 85016
Party NameBacVax, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPhoenix, AZ 85016
Party NameBacVax, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPhoenix, AZ 85016

Trademark Events

Event DateEvent Description
Tuesday, November 9, 2021PUBLISHED FOR OPPOSITION
Saturday, March 13, 2021NEW APPLICATION ENTERED
Thursday, June 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 5, 2021ASSIGNED TO EXAMINER
Tuesday, October 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 20, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 4, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 5, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 5, 2022SOU EXTENSION 1 FILED
Tuesday, July 5, 2022SOU EXTENSION 1 GRANTED
Tuesday, December 13, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 9, 2022SOU TEAS EXTENSION RECEIVED
Friday, December 9, 2022SOU EXTENSION 2 FILED
Friday, December 9, 2022SOU EXTENSION 2 GRANTED
Friday, June 23, 2023SOU TEAS EXTENSION RECEIVED
Friday, June 23, 2023SOU EXTENSION 3 FILED
Friday, June 23, 2023SOU EXTENSION 3 GRANTED
Tuesday, June 27, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 12, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, December 12, 2023SOU EXTENSION 4 FILED
Tuesday, December 12, 2023SOU EXTENSION 4 GRANTED
Thursday, December 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 1, 2024SOU TEAS EXTENSION RECEIVED
Monday, July 1, 2024SOU EXTENSION 5 FILED
Monday, July 1, 2024SOU EXTENSION 5 GRANTED
Monday, December 2, 2024USE AMENDMENT FILED
Thursday, February 13, 2025STATEMENT OF USE PROCESSING COMPLETE
Thursday, February 13, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, March 7, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, March 7, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, April 1, 2025REGISTERED-PRINCIPAL REGISTER
Monday, July 1, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 2, 2024TEAS STATEMENT OF USE RECEIVED
Thursday, July 24, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 24, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 24, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, April 1, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

bacvax development research vaccine